开元官网登录入口

Shanghai, China - On September 30, 2022, Toumai® Laparoscopic Surgical Robot (Toumai^®), independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort^® MedBot^®), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort^®), has accumulatively completed 300 clinical verification surgeries assisted by the surgical robot in the departments of urology, general surgery, gynecology, thoracic surgery and other departments of 22 hospitals in 13 provinces. This achievement indicates that the Toumai^® Four-arm Laparoscopic Surgical Robot has grown mature in clinical applications, and may fully meet the clinical demands on the surgical robots with high level of performance stability, thus helping hospitals make further progress in the scientific research.

As the first four-arm laparoscopic surgery robot developed by a Chinese company and approved for marketing, it takes eight years for MicroPort^® MedBot^® to develop the Toumai^® Laparoscopic Surgical Robot, which has been highly spoken of by surgeons in the clinical application. Toumai^® has assisted the clinical experts in completing a number of challenging surgeries in urology, thoracic surgery, hepatobiliary and pancreatic surgery, gynecology, gastrointestinal surgery. It has assisted clinical experts to achieve many breakthroughs up from zero for Chinese-developed surgical robots, and it has demonstrated extremely high clinical application value with its high adaptability. Toumai^®, with its outstanding strength in advanced technologies and impressive surgical records continuously made, has accelerated the realization of the national strategy of “Substitution of high-end imported medical devices with Chinese-developed products”.

Among the 300 clinical verification surgeries performed by Toumai^®, there are many difficult robot-assisted surgical procedures, as well as many firsts created by Chinese-developed surgical robots, such as: the first Chinese-developed robot-assisted radical prostatectomy, the first Chinese-developed robot-assisted single incision surgery, the first Chinese-developed robot-assisted partial nephrectomy, the first Chinese-developed robot-assisted radical surgery for lung cancer , the first Chinese-developed robot-assisted radical surgery for gastric cancer, the first Chinese-developed robot-assisted radical surgery for kidney cancer, the first Chinese-developed robot-assisted surgery for liver resection, the first Chinese-developed robot-assisted hysterectomy, the first Chinese-developed robot-assisted radical surgery for colon cancer, the world's longest distance 5G remote robotic surgery to date, the first Chinese-developed robot-assisted transabdominal radical prostatectomy, the first Chinese-developed robot-assisted radical prostatectomy via extraperitoneal approach, the first Chinese-developed robot-assisted single-incision partial nephrectomy, the first Chinese-developed robot-assisted distal radical operation for gastric cancer, the first Chinese-developed four-arm robot-assisted sleeve gastrectomy, the first Chinese-developed robot-assisted partial nephrectomy through retroperitoneal approach, the first Chinese-developed robot-assisted renal vein cancer thrombectomy + radical nephrectomy for renal carcinoma, the first Chinese-developed robot-assisted mediastinal tumor resection, the first Chinese-developed robot-assisted radical cystectomy, the first Chinese-developed four-arm robot-assisted cholecystectomy and choledocholithotomy, etc.

The success of these challenging surgeries has proven that the Chinese-developed Toumai^® Laparoscopic Surgical Robot may meet the clinical demands on various surgical methods, and is capable of assisting doctors to complete complex surgeries in narrow anatomical spaces, making it a powerful tool in the hands of clinical experts. It will continue to broaden the clinical application field of Chinese-developed surgical robots and bring high-end and affordable consultation service experience and intelligent surgical solutions to the majority of patients.

On November 1, 2019, a robot-assisted laparoscopic radical prostatectomy (“RALRP”) with Toumai^® was successfully performed for a male patient aged 65 over 1.5 hours. This is the first RALRP completed with a Chinese-developed laparoscopic surgical robot, indicating that the Chinese-developed laparoscopic surgical robot is capable of assisting doctors to complete complex surgeries in narrow anatomical spaces.

On December 30, 2020, a robot-assisted single-incision laparoscopic partial nephrectomy with Toumai^® was successfully performed for a female patient aged 66. The single-incision port channel was implanted via an incision of 3 cm and connected to the robotic arm. The tumor removal and wound suturing were completed with the large 3D surgical view and the flexible robotic arm provided by the Toumai^® Laparoscopic Surgical Robot. It was the first single-incision partial nephrectomy completed by the Toumai^® Laparoscopic Surgical Robot, and also the first single-incision surgery completed by the Chinese-developed laparoscopic surgical robot, signifying another milestone made by the Toumai^® Laparoscopic Surgical Robot in the field of clinical application.

On June 11, 2022, Toumai^® Laparoscopic Surgical Robot successfully completed two ultra-long-distance urinary surgeries across nearly 5,000 kilometers from Kizilsu Kirghiz Autonomous Prefecture, Xinjiang to Nanjing,Jiangsu, realizing the world’s longest distance 5G-based remote robotic surgery so far. The success of this remote surgery fully reflects the R&D technical strength of Chinese-developed surgical robots and shows the breakthrough and leadership of China in the field of 5G-based ultra-long-distance surgery, which is a valuable practice and model innovation in response to the medical system reform of the National Health Commission and a big step forward on the way to realize the sinking of high-quality medical resources.

On September 28, 2022, Toumai® Laparoscopic Surgical Robot successfully assisted the surgeons completing the first left renal vein cancer thrombectomy + left radical nephrectomy for renal cancer, which is a extremely difficult and high-risk surgery in the field of urinary surgery. Previously, there was only cases completed by the surgeons with the imported surgical robot. The success of this surgery has proven the capability of Toumai® Laparoscopic Surgical Robot in assisting highly challenging surgeries in the field of urinary surgery. While we celebrate the 73^rd anniversary of the founding of the People's Republic of China, it is a tribute to our great country that Toumai® Laparoscopic Surgical Robot has once again assisted Chinese surgeons breaking the oversea monopoly of completing challenging surgeries, which is also a significant milestone in the development of our Chinese-developed surgical robots.

The success of 300 clinical verification surgeries with the help of Toumai^® is a testament to its reliable and stable performance for difficult clinical work. The advantages of Toumai^® such as glass-free 3D vision , high-power tissue magnification, flexible robotic arms, and intuitive movement enable the operators to get access to the most realistic surgical experience and simultaneous eye-hand-instrument coordination during the procedure; and the rotatable wrist surgical instrument, which is more flexible than the human hand, can perform the reverse joint operation that is impossible for human wrists, thus helping the operators to perform more delicate and minimally invasive surgical operations.

At the same time， through professional and efficient one-stop services including clinical education and training, customer service, and clinical support, and in combination of innovative robotic surgery teaching model such as mobile training and demonstration platform, MicroPort^® MedBot^® team helps facilitate the access of superior medical resource and robotic surgery operation training resource to wider areas. While bringing benefits to more patients, this also help increase the operation efficiency and the ward turnover rate of all levels of hospitals, thus increasing the level and service value of robotic medicine in the hospitals.

Mr. Yu Liu, Executive Vice President and Chief Commercial Officer of MicroPort^® MedBot^®, said, “Since the completion of the first FIM in November 2019, Toumai® Four-arm Laparoscopic Surgical Robot has helped the surgeons complete 300 clinical verification surgeries. Many of them are highly challenging, and a series of records for Chinese-developed surgical robots are made. The excellent performance of Toumai^® in the clinical projects is a testament to its outstanding safety, effectiveness and stability. It also shows that’Intelligent Manufacturing in China’ is reaching the international leading level in terms of precision and technology. With the National Day approaching, MicroPort^® MedBot^® will pay a tribute to our great country with our Chinese-developed surgical robots that keeps innovating and challenging difficult surgeries, which may help the surgeons around the country continuously increase clinical research level and innovation capability. Staying true to our original aspiration to ‘Make Surgery Easier, Safer and Less Invasive’, we will continue to bring benefits to more patients.”